The Asia Pacific Theranostics Market would witness market growth of 16.2% CAGR during the forecast period (2023-2030).
The China market dominated the Asia Pacific Theranostics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $351.8 million by 2030. The Japan market is registering a CAGR of 15.6% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 17% during (2023 - 2030).
Imaging modalities such as functional MRI (fMRI), diffusion tensor imaging (DTI), and amyloid PET imaging enable visualization of brain structure, function, and pathology, aiding in diagnosing and monitoring neurodegenerative diseases. Biomarker-based assays, including cerebrospinal fluid (CSF) analysis and neuroimaging markers, provide diagnostic and prognostic information for neurologic conditions. Theranostic approaches help identify therapeutic targets and guide personalized treatment strategies for neurological disorders, facilitating early intervention and disease modification.
Theranostics are increasingly being explored for diagnosing and managing infectious diseases, including bacterial, viral, and fungal infections. Diagnostic techniques such as nucleic acid amplification tests (NAATs), serological assays, and imaging modalities enable rapid and accurate detection of infectious agents and assessment of disease severity. Theranostic approaches help identify antimicrobial resistance patterns, guide antibiotic stewardship initiatives, and optimize antimicrobial therapy for infectious diseases.
The expansion of healthcare expenditure in Australia enables greater access to advanced diagnostic and therapeutic technologies, including these, for patients nationwide. According to data released by the Australian government, the nation spent an estimated $241.3 billion, or almost $9,365 per person, on health-related products and services in 2021–2022. The total amount spent on recurrent and capital health care increased by 6.0% in real terms (adjusted for inflation) compared to 2020–21. Thus, the increasing expenditure in the healthcare sector and the growing elderly population drive the market’s growth.
Free Valuable Insights: The Global Theranostics Market is Predict to reach USD 5.4 Billion by 2030, at a CAGR of 15.2%
Based on End User, the market is segmented into Hospitals & Cancer Care Centers, Theranostics Centers, and Research & Academic Centers. Based on Product, the market is segmented into Radiopharmaceuticals, Diagnostic Imaging, IVD/Biomarker Screening, and Software & Services. Based on Application, the market is segmented into Prostate Cancer, Bone Metastasis, Other Cancers, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
By End User
By Product
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
